Lower persistence of anti-nucleocapsid compared to anti-spike antibodies up to one year after SARS-CoV-2 infection
- Author
- Jan Van Elslande, Matthijs Oyaert (UGent) , Natalie Lorent, Yannick Vande Weygaerde (UGent) , Gijs Van Pottelbergh, Lode Godderis, Marc Van Ranst, Emmanuel André, Elizaveta Padalko (UGent) , Katrien Lagrou, Stien Vandendriessche (UGent) and Pieter Vermeersch
- Organization
- Abstract
- We retrospectively compared the long-term evolution of IgG anti-spike (S) and anti-nucleocapsid (N) levels (Abbott immunoassays) in 116 non-severe and 115 severe SARS-CoV-2 infected patients from 2 university hospitals up to 365 days post positive RT-PCR. IgG anti-S and anti-N antibody levels decayed exponentially up to 365 days after a peak 0 to 59 days after positive RT-PCR. Peak antibody level/cut-off ratio 0 to 59 days after positive RT-PCR was more than 70 for anti-S compared to less than 6 for anti-N (P < 0.01). Anti-S and anti-N were significantly higher in severe compared to non-severe patients up to 180 to 239 days and 300 to 365 days, respectively (P < 0.05). Despite similar half-lives, the estimated time to 50% seronegativity was more than 2 years for anti-S compared to less than 1 year for anti-N in non-severe and severe COVID-19 patients, due to the significantly higher peak antibody level/cut-off ratio for anti-S compared to anti-N.
- Keywords
- Infectious Diseases, Microbiology (medical), General Medicine, SARS-CoV-2, COVID-19 testing, COVID-19, Serological Testing, Immunoassay, Spike, Nucleocapsid, IgG
Downloads
-
(...).pdf
- full text (Published version)
- |
- UGent only
- |
- |
- 2.35 MB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-8746355
- MLA
- Van Elslande, Jan, et al. “Lower Persistence of Anti-Nucleocapsid Compared to Anti-Spike Antibodies up to One Year after SARS-CoV-2 Infection.” DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, vol. 103, no. 1, 2022, doi:10.1016/j.diagmicrobio.2022.115659.
- APA
- Van Elslande, J., Oyaert, M., Lorent, N., Vande Weygaerde, Y., Van Pottelbergh, G., Godderis, L., … Vermeersch, P. (2022). Lower persistence of anti-nucleocapsid compared to anti-spike antibodies up to one year after SARS-CoV-2 infection. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 103(1). https://doi.org/10.1016/j.diagmicrobio.2022.115659
- Chicago author-date
- Van Elslande, Jan, Matthijs Oyaert, Natalie Lorent, Yannick Vande Weygaerde, Gijs Van Pottelbergh, Lode Godderis, Marc Van Ranst, et al. 2022. “Lower Persistence of Anti-Nucleocapsid Compared to Anti-Spike Antibodies up to One Year after SARS-CoV-2 Infection.” DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE 103 (1). https://doi.org/10.1016/j.diagmicrobio.2022.115659.
- Chicago author-date (all authors)
- Van Elslande, Jan, Matthijs Oyaert, Natalie Lorent, Yannick Vande Weygaerde, Gijs Van Pottelbergh, Lode Godderis, Marc Van Ranst, Emmanuel André, Elizaveta Padalko, Katrien Lagrou, Stien Vandendriessche, and Pieter Vermeersch. 2022. “Lower Persistence of Anti-Nucleocapsid Compared to Anti-Spike Antibodies up to One Year after SARS-CoV-2 Infection.” DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE 103 (1). doi:10.1016/j.diagmicrobio.2022.115659.
- Vancouver
- 1.Van Elslande J, Oyaert M, Lorent N, Vande Weygaerde Y, Van Pottelbergh G, Godderis L, et al. Lower persistence of anti-nucleocapsid compared to anti-spike antibodies up to one year after SARS-CoV-2 infection. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE. 2022;103(1).
- IEEE
- [1]J. Van Elslande et al., “Lower persistence of anti-nucleocapsid compared to anti-spike antibodies up to one year after SARS-CoV-2 infection,” DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, vol. 103, no. 1, 2022.
@article{8746355,
abstract = {{We retrospectively compared the long-term evolution of IgG anti-spike (S) and anti-nucleocapsid (N) levels (Abbott immunoassays) in 116 non-severe and 115 severe SARS-CoV-2 infected patients from 2 university hospitals up to 365 days post positive RT-PCR. IgG anti-S and anti-N antibody levels decayed exponentially up to 365 days after a peak 0 to 59 days after positive RT-PCR. Peak antibody level/cut-off ratio 0 to 59 days after positive RT-PCR was more than 70 for anti-S compared to less than 6 for anti-N (P < 0.01). Anti-S and anti-N were significantly higher in severe compared to non-severe patients up to 180 to 239 days and 300 to 365 days, respectively (P < 0.05). Despite similar half-lives, the estimated time to 50% seronegativity was more than 2 years for anti-S compared to less than 1 year for anti-N in non-severe and severe COVID-19 patients, due to the significantly higher peak antibody level/cut-off ratio for anti-S compared to anti-N.}},
articleno = {{115659}},
author = {{Van Elslande, Jan and Oyaert, Matthijs and Lorent, Natalie and Vande Weygaerde, Yannick and Van Pottelbergh, Gijs and Godderis, Lode and Van Ranst, Marc and André, Emmanuel and Padalko, Elizaveta and Lagrou, Katrien and Vandendriessche, Stien and Vermeersch, Pieter}},
issn = {{0732-8893}},
journal = {{DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE}},
keywords = {{Infectious Diseases,Microbiology (medical),General Medicine,SARS-CoV-2,COVID-19 testing,COVID-19,Serological Testing,Immunoassay,Spike,Nucleocapsid,IgG}},
language = {{eng}},
number = {{1}},
pages = {{8}},
title = {{Lower persistence of anti-nucleocapsid compared to anti-spike antibodies up to one year after SARS-CoV-2 infection}},
url = {{http://doi.org/10.1016/j.diagmicrobio.2022.115659}},
volume = {{103}},
year = {{2022}},
}
- Altmetric
- View in Altmetric
- Web of Science
- Times cited: